Literature DB >> 21831659

Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes.

Manuela Battaglia1, Maria-Grazia Roncarolo.   

Abstract

In type 1 diabetes (T1D), insulin-producing pancreatic β-cells are attacked and destroyed by the immune system. Although man-made insulin is life-saving, it is not a cure and it cannot prevent long-term complications. In addition, most T1D patients would do almost anything to achieve release from the burden of daily glucose monitoring and insulin injection. Despite the formation of very large and promising clinical trials, a means to prevent/cure T1D in humans remains elusive. This has led to an increasing interest in the possibility of using T cells with regulatory properties (Treg cells) as a biological therapy to preserve and restore tolerance to self-antigens. In the present review we will attempt to consolidate learning from the past and to describe what we now believe could in the future become a successful Treg-cell based immune intervention in T1D.
Copyright © 2011. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21831659     DOI: 10.1016/j.smim.2011.07.007

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  18 in total

Review 1.  Regulatory immune cells in transplantation.

Authors:  Kathryn J Wood; Andrew Bushell; Joanna Hester
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 2.  miRNAs: novel regulators of autoimmunity-mediated pancreatic β-cell destruction in type 1 diabetes.

Authors:  Ying Zheng; Zhen Wang; Zhiguang Zhou
Journal:  Cell Mol Immunol       Date:  2017-03-20       Impact factor: 11.530

3.  Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.

Authors:  Michelle Rosenzwajg; Guillaume Churlaud; Roberto Mallone; Adrien Six; Nicolas Dérian; Wahiba Chaara; Roberta Lorenzon; S Alice Long; Jane H Buckner; Georgia Afonso; Hang-Phuong Pham; Agnès Hartemann; Aixin Yu; Alberto Pugliese; Thomas R Malek; David Klatzmann
Journal:  J Autoimmun       Date:  2015-01-26       Impact factor: 7.094

Review 4.  Prevention and treatment of type 1 diabetes mellitus by the manipulation of invariant natural killer T cells.

Authors:  Jan Novak; Lucie Novakova
Journal:  Clin Exp Med       Date:  2012-07-24       Impact factor: 3.984

Review 5.  Regulatory T cells in the immunotherapy of melanoma.

Authors:  Zhengxiao Ouyang; Hongwei Wu; Linqin Li; Yi Luo; Xianan Li; Gang Huang
Journal:  Tumour Biol       Date:  2015-10-30

Review 6.  Alteration of regulatory T cells in type 1 diabetes mellitus: a comprehensive review.

Authors:  Tingting Tan; Yufei Xiang; Christopher Chang; Zhiguang Zhou
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

Review 7.  Vaccine against autoimmune disease: antigen-specific immunotherapy.

Authors:  Robert P Anderson; Bana Jabri
Journal:  Curr Opin Immunol       Date:  2013-03-13       Impact factor: 7.486

8.  Regulatory T cells and the control of the allergic response.

Authors:  Ana Agua-Doce; Luis Graca
Journal:  J Allergy (Cairo)       Date:  2012-09-29

9.  Translating tolerogenic therapies to the clinic - where do we stand?

Authors:  Fadi Issa; Kathryn J Wood
Journal:  Front Immunol       Date:  2012-08-20       Impact factor: 7.561

10.  Cell-Mediated Immunity in Elite Controllers Naturally Controlling HIV Viral Load.

Authors:  Luca Genovese; Manuela Nebuloni; Massimo Alfano
Journal:  Front Immunol       Date:  2013-04-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.